clinical trial · NCT07548450
Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)
Waldenstrom MacroglobulinemiaPirtobrutinibMosunetuzumab
brief summary
The purpose of this clinical trial it to test the safety and tolerability of the study drugs mosunetuzumab in combination with pirtobrutinib in patients with relapsed or refractory Waldenstrom's Macroglobulinemia.
started
Jun 1, 2026
primary completion
Jun 1, 2034
completion
Jun 1, 2035
last updated
Apr 23, 2026
official title
A Phase II Study of Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol